摘要
目的分析尼可地尔联合沙库巴曲缬沙坦治疗慢性心力衰竭的价值,帮助患者提升心肌功能,改善临床症状。方法随机将78例慢性心力衰竭患者分为试验组和对照组,每组39例。试验组采用尼可地尔联合沙库巴曲缬沙坦治疗,对照组采用沙库巴曲缬沙坦治疗。对比两组疗效、心功能指标[左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]、心力衰竭标志物[基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶组织抑制因子-1(TIMP-1)以及N末端B型利钠肽前体(NT-proBNP)]。结果试验组总有效率为94.87%,对照组仅76.92%,与对照组对比,试验组总有效率更高(P<0.05)。治疗后,试验组LVEF为(47.36±5.03)%,对照组为(42.38±4.79)%;试验组LVEDD为(44.05±3.18)mm,对照组为(49.74±5.23)mm。与对照组对比,试验组LVEF更高,LVEDD更小(P<0.05)。治疗后,试验组NT-proBNP、MMP-2、TIMP-1水平分别为(263.46±51.48)ng/L、(152.25±2.14)μg/L、(357.28±19.09)μg/L,对照组分别为(434.87±51.42)ng/L、(186.68±2.19)μg/L、(194.65±15.25)μg/L。与对照组对比,试验组NT-proBNP、MMP-2水平更低,TIMP-1水平更高(P<0.05)。结论慢性心力衰竭患者联用尼可地尔和沙库巴曲缬沙坦治疗疗效更高,心功能改善也更加明显,有助于控制疾病进展,值得推广。
Objective To analyze the value of combining nicorandil and sacubitril/valsartan in the treatment of chronic heart failure,help patients improve myocardial function and improve clinical symptoms.Methods A total of 78 patients with chronic heart failure were randomly divided into the experimental group and the control group,with 39 cases in each group.The experimental group was treated with nicorandil combined with sacubitril/valsartan,while the control group was treated with sacubitril/valsartan.Comparison of therapeutic effects,cardiac function indicators[left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],and heart failure markers[matrix metalloproteinase-2(MMP-2),tissue inhibitor of matrix metalloproteinase-1(TIMP-1),and N-terminal pro-B-type natriuretic peptide(NTproBNP)]between the two groups.Results The total effective rate of the experimental group was 94.87%,while that of the control group was only 76.92%.Compared with the control group,the total effective rate of the experimental group was higher(P<0.05).After treatment,the LVEF of the experimental group was(47.36±5.03)%,and that of the control group was(42.38±4.79)%.The LVEDD of the experimental group was(44.05±3.18)mm,and that of the control group was(49.74±5.23)mm.Compared with the control group,the LVEF of the experimental group was higher and the LVEDD was smaller(P<0.05).After treatment,the levels of NT-proBNP,MMP-2 and TIMP-1 in the experimental group were(263.46±51.48)ng/L,(152.25±2.14)μg/L and(357.28±19.09)μg/L,and those in the control groups were(434.87±51.42)ng/L,(186.68±2.19)μg/L,and(194.65±15.25)μg/L.Compared with the control group,the levels of NT-proBNP and MMP-2 in the experimental group were lower,and the level of TIMP-1 was higher(P<0.05).Conclusion The combination of nicorandil and sacubitril/valsartan for patients with chronic heart failure has a higher therapeutic effect,and the improvement of cardiac function is more obvious.It is helpful to control the progression of the disease,and is worthy of promotion.
作者
杨再鑫
YANG Zai-xin(Beijing Huairou Hospital,Beijing 101400,China)
出处
《中国实用医药》
2025年第20期98-101,共4页
China Practical Medicine
